Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

EVMN

Evommune Inc

Nov 14 • 04:00PM ET

18.30

+0.08 0.44 %

Healthcare • Biotechnology • USA • NYSE

Index	-	P/E	-	EPS (ttm)	-	Insider Own	43.86%	Shs Outstand	30.08M	Perf Week	-0.60%
Market Cap	550.46M	Forward P/E	-	EPS next Y	-	Insider Trans	0.00%	Shs Float	16.89M	Perf Month	-
Enterprise Value	721.48M	PEG	-	EPS next Q	-	Inst Own	9.30%	Short Float	-	Perf Quarter	-
Income	-	P/S	-	EPS this Y	-	Inst Trans	-	Short Ratio	-	Perf Half Y	-
Sales	-	P/B	-	EPS next Y	-	ROA	-	Short Interest	-	Perf YTD	-9.54%
Book/sh	-5.69	P/C	6.34	EPS next 5Y	-	ROE	-	52W High	24.03 -23.85%	Perf Year	-
Cash/sh	2.89	P/FCF	-	EPS past 3/5Y	- -	ROIC	-	52W Low	16.70 9.58%	Perf 3Y	-
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	8.39% -	Perf 5Y	-
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	-	Oper. Margin	-	ATR (14)	2.47	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	9.40	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	-	Recom	-
Dividend Gr. 3/5Y	- -	Current Ratio	9.40	EPS Q/Q	-	SMA20	-4.02%	Beta	-	Target Price	-
Payout	-	Debt/Eq	-	Sales Q/Q	-	SMA50	-4.02%	Rel Volume	0.30	Prev Close	18.22
Employees	41	LT Debt/Eq	-	Earnings	-	SMA200	-4.02%	Avg Volume	552.42K	Price	18.30
IPO	Nov 06, 2025	Option/Short	No / Yes	EPS/Sales Surpr.	- -	Trades		Volume	167,882	Change	0.44%

Nov-06-25 03:39PM	What Shutdown? The IPO Window Is Still Open for Some Companies (Barrons.com)
08:55AM	NYSE Content Advisory: Pre-Market Update + Evommune & Aeromexico Begin Trading (PR Newswire)
Nov-05-25 07:45PM	Evommune Announces Pricing of its Initial Public Offering (PR Newswire)

Evommune, Inc. is a clinical-stage biotechnology company. It engages in the development of medicines for inflammatory diseases. The company was founded by Luis C. Pena, Eugene Andrew Bauer, and Hans Hofland in 2020 and is headquartered in Palo Alto, CA.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

EVMN

Evommune Inc

Upgrade your FINVIZ experience